Dr. Mehra is a Clinical Professor of Pathology at Michigan Medicine and Faculty Member of the Michigan Center for Translational Pathology (MCTP). As a genitourinary pathologist, Dr. Mehra serves as a regional and national consultant and regularly reviews extramural consultations. As Genitourinary service line director for MLabs, Michigan Medicine's reference laboratory division, and Director, MCTP Esoteric Clinical Laboratory Services where he oversees the development of novel assays in Genitourinary Oncology, Dr. Mehra works to solve diagnostic problems, both common and rare. He has helped launch clinically significant molecular oncology results into assays for diagnostic, prognostic, and/or therapeutic use.

Focusing on the discovery of gene aberrations in genitourinary tumors and development of related biomarkers, Dr. Mehra played an important role early on in discovery of recurrent fusion of TMPRSS2 and ETS transcription factor genes. These genes are now recognized as an important driver mutation in prostate cancer. His more recent work has helped characterize uncommon and common renal tumors at the clinicopathologic and molecular level. Over the last decade, he has served as the author of more than 150 publications in the peer-reviewed literature, several book chapters, and abstracts. Dr. Mehra has delivered numerous invited national and international presentations.

Participating in projects with, and providing peer-review services to, organizations like the Prostate Cancer Foundation (PCF), Genitourinary Pathology Society (GUPS), United States and Canadian Academy of Pathology (USCAP), and The Cancer Genome Atlas (TCGA), Dr. Mehra has contributed to several multidisciplinary NIH-funded and non-NIH-funded projects investigating clinical and translational aspects of genitourinary malignancies. Additionally, Dr. Mehra directs the Michigan Legacy Tissue Program (MLTP) at Michigan Medicine, which helps patients and their families make a lasting impact in the lives of future patients, giving others a better chance at life by participating in clinical cancer research.